The Effects of Hesperidin and Flaxseed in Prediabetes
Overview
To study the effects of Hesperidin and flaxseed supplement in patients with prediabetes, 50 patients will be randomly allocated to control group or 2 capsules Hesperidin and 30 gram flaxseed for 12 weeks; both groups will be advised to adherence the investigators' diet and exercise program too. At the first and the end of the intervention, lipid profiles, blood pressure, blood sugar, inflammatory and anthropometric factors will be assessed and compared between groups.
Full Title of Study: “Evaluation of the Effects of Hesperidin and Flaxseed Supplementation in Patients With Prediabetes”
Study Type
- Study Type: Interventional
- Study Design
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Primary Purpose: Treatment
- Masking: None (Open Label)
- Study Primary Completion Date: October 1, 2018
Interventions
- Dietary Supplement: hesperidin and flaxseed
- 2 capsuls hesperidin and 30 g flaxseed
- Other: control
- no supplementation
Arms, Groups and Cohorts
- Active Comparator: hesperidin and flaxseed
- Placebo Comparator: control
Clinical Trial Outcome Measures
Primary Measures
- prediabetes
- Time Frame: 12 weeks
- number of participants with normal plasma glucose
Participating in This Clinical Trial
Inclusion Criteria
- Age of 18 to 70 years prediabetes: impaired fasting glucose (>100 mg/dL) and/or HbA1C 5.7% to 6.5%, and overweight or obese with body mass index range of 25 to 40 kg/m2 Exclusion Criteria:
- pregnancy or lactation – A history of Cardiovascular disease, Pulmonary disease, Renal disease & Celiac disease; Cirrhosis – Following program to lose weight in recent 3 mo
Gender Eligibility: All
Minimum Age: 18 Years
Maximum Age: 70 Years
Are Healthy Volunteers Accepted: No
Investigator Details
- Lead Sponsor
- National Nutrition and Food Technology Institute
- Provider of Information About this Clinical Study
- Principal Investigator: Dr Azita Hekmatdoost, Principal Investigator – National Nutrition and Food Technology Institute
Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.